KCNAB2 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
natural killer cell	20 studies	22% ± 5%	Explore
macrophage	17 studies	24% ± 6%	Explore
CD8-positive, alpha-beta T cell	17 studies	22% ± 5%	Explore
non-classical monocyte	16 studies	27% ± 11%	Explore
classical monocyte	14 studies	25% ± 9%	Explore
regulatory T cell	14 studies	19% ± 3%	Explore
CD16-positive, CD56-dim natural killer cell, human	13 studies	27% ± 5%	Explore
CD16-negative, CD56-bright natural killer cell, human	13 studies	22% ± 4%	Explore
CD4-positive, alpha-beta T cell	12 studies	21% ± 7%	Explore
monocyte	10 studies	27% ± 7%	Explore
CD8-positive, alpha-beta memory T cell	9 studies	21% ± 5%	Explore
T cell	9 studies	21% ± 5%	Explore
dendritic cell	9 studies	26% ± 13%	Explore
conventional dendritic cell	8 studies	28% ± 12%	Explore
glutamatergic neuron	8 studies	44% ± 21%	Explore
plasmacytoid dendritic cell	8 studies	22% ± 7%	Explore
myeloid cell	8 studies	31% ± 16%	Explore
gamma-delta T cell	8 studies	21% ± 4%	Explore
effector memory CD8-positive, alpha-beta T cell	7 studies	19% ± 3%	Explore
mature NK T cell	7 studies	19% ± 2%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	7 studies	20% ± 4%	Explore
mucosal invariant T cell	7 studies	19% ± 2%	Explore
alveolar macrophage	6 studies	32% ± 14%	Explore
GABAergic neuron	6 studies	39% ± 17%	Explore
hematopoietic precursor cell	5 studies	29% ± 8%	Explore
effector CD8-positive, alpha-beta T cell	5 studies	26% ± 5%	Explore
lymphocyte	4 studies	30% ± 7%	Explore
effector CD4-positive, alpha-beta T cell	4 studies	25% ± 11%	Explore
effector memory CD4-positive, alpha-beta T cell	4 studies	20% ± 3%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	4 studies	22% ± 4%	Explore
CD4-positive, alpha-beta memory T cell	4 studies	27% ± 5%	Explore
exhausted T cell	3 studies	27% ± 7%	Explore
neuron	3 studies	27% ± 7%	Explore
endothelial cell	3 studies	31% ± 6%	Explore
microglial cell	3 studies	18% ± 3%	Explore
retinal ganglion cell	3 studies	51% ± 16%	Explore
common myeloid progenitor	3 studies	32% ± 5%	Explore
hematopoietic stem cell	3 studies	27% ± 3%	Explore
mononuclear phagocyte	3 studies	20% ± 2%	Explore
intermediate monocyte	3 studies	36% ± 13%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	3 studies	19% ± 2%	Explore
interneuron	3 studies	38% ± 19%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	10 studies	20% ± 3%	Explore
brain	6 studies	35% ± 17%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
brain	96%	17618.14	2547 / 2642	100%	15.74	702 / 705
lung	98%	6261.27	569 / 578	94%	6.47	1082 / 1155
kidney	75%	3843.00	67 / 89	85%	6.26	764 / 901
intestine	54%	1747.33	525 / 966	86%	6.00	455 / 527
skin	37%	756.76	662 / 1809	99%	48.03	468 / 472
esophagus	36%	732.12	520 / 1445	90%	5.48	164 / 183
breast	41%	1015.59	188 / 459	84%	4.29	936 / 1118
adrenal gland	41%	859.38	107 / 258	81%	7.50	186 / 230
bladder	48%	938.38	10 / 21	71%	4.12	360 / 504
stomach	18%	334.77	64 / 359	95%	7.45	272 / 286
uterus	26%	514.19	45 / 170	84%	4.16	384 / 459
thymus	23%	598.81	149 / 653	84%	5.16	511 / 605
eye	0%	0	0 / 0	100%	111.90	80 / 80
lymph node	0%	0	0 / 0	100%	30.48	29 / 29
spleen	100%	12948.49	241 / 241	0%	0	0 / 0
peripheral blood	100%	14514.20	925 / 929	0%	0	0 / 0
ovary	14%	263.46	25 / 180	85%	4.54	366 / 430
tonsil	0%	0	0 / 0	93%	6.30	42 / 45
prostate	32%	661.58	78 / 245	61%	1.96	307 / 502
pancreas	2%	67.27	7 / 328	89%	6.02	159 / 178
liver	20%	500.39	46 / 226	57%	4.08	230 / 406
adipose	71%	2132.89	854 / 1204	0%	0	0 / 0
heart	57%	1653.75	494 / 861	0%	0	0 / 0
blood vessel	28%	747.22	368 / 1335	0%	0	0 / 0
muscle	24%	967.28	191 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_1901379	Biological process	regulation of potassium ion transmembrane transport
GO_0098900	Biological process	regulation of action potential
GO_2000008	Biological process	regulation of protein localization to cell surface
GO_0071805	Biological process	potassium ion transmembrane transport
GO_0070995	Biological process	NADPH oxidation
GO_0035579	Cellular component	specific granule membrane
GO_0005886	Cellular component	plasma membrane
GO_0005874	Cellular component	microtubule
GO_0016020	Cellular component	membrane
GO_0009898	Cellular component	cytoplasmic side of plasma membrane
GO_1990031	Cellular component	pinceau fiber
GO_0005829	Cellular component	cytosol
GO_0045202	Cellular component	synapse
GO_0070821	Cellular component	tertiary granule membrane
GO_0044224	Cellular component	juxtaparanode region of axon
GO_0008076	Cellular component	voltage-gated potassium channel complex
GO_0005249	Molecular function	voltage-gated potassium channel activity
GO_0004033	Molecular function	aldo-keto reductase (NADPH) activity
GO_0015459	Molecular function	potassium channel regulator activity
GO_0044325	Molecular function	transmembrane transporter binding
GO_0005515	Molecular function	protein binding

IV. Literature review

[source]

Gene name	KCNAB2
Protein name	Potassium voltage-gated channel subfamily A regulatory beta subunit 2 Voltage-gated potassium channel subunit beta-2 (K(+) channel subunit beta-2) (Kv-beta-2) Voltage-gated potassium channel subunit beta-2 (EC 1.1.1.-) (K(+) channel subunit beta-2) (Kv-beta-2) (hKvbeta2)
Synonyms	KCNA2B KCNK2
Description	FUNCTION: Cytoplasmic potassium channel subunit that modulates the characteristics of the channel-forming alpha-subunits . Contributes to the regulation of nerve signaling, and prevents neuronal hyperexcitability (By similarity). Promotes expression of the pore-forming alpha subunits at the cell membrane, and thereby increases channel activity (By similarity). Promotes potassium channel closure via a mechanism that does not involve physical obstruction of the channel pore . Promotes KCNA4 channel closure . Modulates the functional properties of KCNA5 (By similarity). Enhances KCNB2 channel activity (By similarity). Binds NADPH and has NADPH-dependent aldoketoreductase activity (By similarity). Has broad substrate specificity and can catalyze the reduction of methylglyoxal, 9,10-phenanthrenequinone, prostaglandin J2, 4-nitrobenzaldehyde, 4-nitroacetophenone and 4-oxo-trans-2-nonenal (in vitro) (By similarity). .
Accessions	ENST00000662363.1 K7EKU4 ENST00000662147.1 Q5TG81 ENST00000671676.1 [Q13303-1] Q5TG78 ENST00000658883.1 ENST00000669250.1 [Q13303-2] ENST00000652845.1 K7EIR5 A0A590UJ72 ENST00000655703.1 ENST00000668706.1 ENST00000662815.1 A0A590UJV4 A0A590UJJ4 ENST00000378083.8 [Q13303-3] A0A590UK89 A0A5F9UN28 Q6FG44 ENST00000666299.1 ENST00000668559.1 [Q13303-5] ENST00000164247.5 [Q13303-1] ENST00000602612.5 [Q13303-5] ENST00000666163.1 [Q13303-2] A0A590UJB6 ENST00000655548.1 A0A590UJU1 A0A590UJY1 ENST00000352527.6 [Q13303-2] A0A590UJ35 A0A590UJ79 A0A590UJB8 ENST00000656198.1 ENST00000656746.1 ENST00000663169.1 ENST00000653262.1 Q5TG84 A0A590UJU4 ENST00000428161.7 [Q13303-1] Q13303 ENST00000462676.3 A0A590UJK5 ENST00000378097.6 [Q13303-1] ENST00000389632.9 ENST00000378092.6 [Q13303-1] Q6FG22 A0A590UJ15 ENST00000671076.1 ENST00000445501.6 ENST00000658691.1 ENST00000472700.7 ENST00000378111.6 ENST00000341524.6 A0A590UJI8 A0A590UJX9 ENST00000458166.6 [Q13303-4]

KCNAB2 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review